News
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
ImmunoPrecise Antibodies (NASDAQ: IPA) has named Kristin Taylor as its Chief Financial Officer, effective immediately. Taylor, who has served as interim CFO since September 19, 2023, brings extensive experience from early-stage and high-growth companies, including Bay West and B-MoGen Biotechnologies. She has experience in growth strategies, fundraising, due diligence, financial analysis and compliance. Taylor holds an MBA from the Carlson School of Management and a bachelor’s degree in Business Administration. She is also a Certified Public Accountant (inactive). IPA CEO Jennifer Bath praised Taylor’s performance during her interim tenure and expressed confidence in her ability to lead the company’s financial operations.
Positive
- Kristin Taylor’s appointment as CFO brings with her extensive experience in financial leadership.
- Taylor’s experience in growth strategies and value creation is expected to benefit IPA.
- His performance as interim CFO was strong, indicating successful future leadership.
06/27/2024 – 08:01
VICTORIA, British Columbia–(BUSINESS WIRE)–
ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutics research and technology company, is pleased to announce the appointment of Kristin Taylor as Chief Financial Officer, effective immediately. Ms. Taylor has served as interim CFO since September 19, 2023 and will now transition to the role on a permanent basis.
Ms. Taylor is a seasoned financial executive with extensive experience in early-stage and high-growth companies, including those privately held, private equity-backed and publicly listed. She has solid experience in driving growth, establishing infrastructure and implementing effective strategies for value creation in dynamic and scalable environments. Prior to joining IPA, Ms. Taylor served as Chief Financial Officer of Bay West LLC and B-MoGen Biotechnologies Inc., along with capital markets and liquidity management roles at Prime Therapeutics and Medtronic. Prior to her corporate experience, she held technical and consulting roles in public accounting. His experience spans growth strategy and execution, fundraising and recapitalizations, acquisition due diligence and integration, financial analysis, accounting, auditing and tax compliance, leadership and team development, process development and IT initiatives, and relationships with boards and investors.
Ms. Taylor holds an MBA in Finance and Strategic Management from the University of Minnesota Carlson School of Management, where she was a Carlson Scholar, and a Bachelor of Science in Business Administration with a minor in Accounting and a minor in Communications. She is also a Certified Public Accountant (inactive).
“We are thrilled to welcome Kristin to ImmunoPrecise as our new CFO,” said Jennifer Bath, CEO of IPA. “His extensive experience and proven track record in financial leadership will be invaluable as we continue to drive our growth and strategic initiatives. Her performance during her interim tenure has been exemplary and we are confident in her ability to lead our financial operations.”
About ImmunoPrecise Antibodies Ltd.
The IPA Family is a biotherapeutics research and technology group that utilizes systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include fully seamless and highly specialized therapeutic biologic discovery, development and licensing to support your business partners in their quest to discover and develop new biologics against the most challenging targets. has several subsidiaries in North America and Europe, including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) BV (collectively, the “IPA Family”). For more information, visit www.ipatherapeutics.com.
Source: ImmunoPrecise Antibodies Ltd.
Forward-Looking Statement:
This press release contains forward-looking statements, which are based on current expectations and involve risks and uncertainties. These statements include our expectations regarding the impact of Kristin Taylor as Chief Financial Officer and our future growth and financial performance.
Factors that could cause actual results to differ include economic conditions, regulatory changes and other risks detailed in our filings with securities regulators in the United States and Canada. We undertake no obligation to update these forward-looking statements except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240627304070/en/
Contact with investors: investors@ipatherapeutics.com
Source: ImmunoPrecise Antibodies Ltd.
Common questions
What changes occurred in the management of the IPA in October 2023?
Kristin Taylor has been named IPA’s permanent Chief Financial Officer in October 2023.
Who is Kristin Taylor and what is her role at IPA?
Kristin Taylor is IPA’s newly appointed Chief Financial Officer, effective immediately from October 2023.
What experience does IPA’s new CFO, Kristin Taylor, bring to the company?
Kristin Taylor has extensive experience in financial leadership, including growth strategies, fundraising, due diligence and financial analysis in roles at Bay West and B-MoGen Biotechnologies.
What are Kristin Taylor’s qualifications for her role at IPA?
Kristin Taylor holds an MBA in Finance and Strategic Management from the Carlson School of Management and a bachelor’s degree in Business Administration. She is also a Certified Public Accountant (inactive).
When did Kristin Taylor serve as IPA’s interim CFO?
Kristin Taylor served as IPA’s interim CFO beginning September 19, 2023, prior to her permanent appointment.